🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

5 days. 4 patients to hit green across ALL progression criteria🎈 for evocc_trial IT'S FEASIBLE! Hany Zayed Athanasios Diamantopoulos Paul Moxey Leicester Vascular Research Research at Leicester's Hospitals Daniel Carradice ian chetter Vascular Society

STARS 2024! Join us for a special 10-Year anniversary symposium on 5-6 July in London STARS offers a unique opportunity to engage with a selected national and international faculty discussing critical issues in vascular and endovascular surgery starsymposium.co.uk

TWO! Two more recruits to achieve the highest progression criteria within NIHR. Total recruitment target of 60! Athanasios Saratzis Leicester Clinical Trials Unit

The NIHR KID trial: "Preventing kidney injury using CO2 as contrast medium in patients with Peripheral Arterial Disease (PAD) & Chronic Kidney Disease (CKD) having arterial intervention" - we now have a logo! Supported by #LCTU.

🔔 Join Dr Adams, Dr Diamantopoulos Athanasios Diamantopoulos & Dr Migliara at the Cordis Symposium @CX2024! Discover advancements in PAD treatment with Sirolimus Eluting Balloons. Uncover latest data & gain insights from clinical cases. Don't miss it! #CLIFighters #IRad #PAD #DEB CLIfighters

The next instalment in our BSIR 2024 Webinar Series will see us partner with Boston Scientific EMEA - Cardiology, for BASIL 3: The Discussion. The webinar will take place on Wednesday 1st May at 7pm. Register here - tinyurl.com/ykzvbau7

evocc_trial Collaborators - please do not forget to screen & recruit... May has been a bit slower than expected in terms of recruitment. Let us know if we can help in some way: [email protected]

Dear friends and colleagues, I am standing for member of the CIRSE CIRSE SOP committee this year. Voting is open and any support will be very much appreciated The British Society of Interventional Radiology BSIR Trainees (British Society of IR Trainees)

Amazing Well done to everyone

THANK YOU to each and every one who has been a part of this wonderful journey🙏🙏

Happy to be elected as member of the SOP committee CIRSE . Thank you all for the incredible support.

EVOCC evocc_trial in July 2024: 18 NHS sites open 83 participants recruited ... we are actively looking for new sites (email: [email protected]) ... and PLEASE (active sites) continue the effort; June & July have been slow months. Do not forget to screen & randomise!

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-2 Trial: Analysis of the Timing and Causes of Death in Participants Randomised to an Infrapopliteal Vein Bypass or Best Endovascular Treatment First Revascularisation Strategy - ScienceDirect sciencedirect.com/science/articl…

If each open evocc_trial site recruits 0.8 patients between now & end of the summer, we will have hit 100 participants. Support the cause!

Explore the future of vascular intervention, in a new residential meeting focussed on innovative technologies, research and treatment strategies. Prof Mo Hamady and Dr Raghu Lakshminarayan invite you to secure your place at the inaugural VITALS meeting. tinyurl.com/mak372ye

Explore the future of vascular intervention, in a new residential meeting focussed on innovative technologies, research and treatment strategies. Prof Mo Hamady and Dr Raghu Lakshminarayan invite you to secure your place at the inaugural VITALS meeting. tinyurl.com/mak372ye

Starting recruitment soon: KID National Institute for Health and Care Research trial: Does the use of CO2 via Angiodroid injection reduce acute kidney injury in #PAD endovascular/hybrid procedures? IR & vascular teams from Hull, Stoke, Leicester, STH, SGH the 1st to take part... starting in November!

>160 participants in evocc_trial now across 25 🇬🇧 hospitals. >70% of patients approached say YES to randomisation, accepting both open & endovascular treatment. Don't deny patients their choice! 😔 ...offering everyone participation in an RCT is crucial.